The DOI matches its Crossref record.
Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life
Abstract
OBJECTIVE: To find a dose of fluconazole for very low birth weight infants during an outbreak of Candida parapsilosis. METHODS: Twelve premature infants (mean gestational age, 27.4 weeks; mean birth weight, 912 gm) receiving fluconazole prophylactically from the first day of life were enrolled in an open phase I-II pharmacokinetics, safety, and tolerance trial. Up to 5 doses of 6 mg/kg were administered intravenously every 72 hours during the first 2 weeks of life. Pharmacokinetic characteristics of fluconazole were determined after the first, third, and fifth doses. RESULTS: The mean peak and trough concentrations after the 3 doses were 5.5 and 2.6 micrograms/ml, 12.8 and 4.3 micrograms/ml, and 10.0 and 2.9 micrograms/ml (p = 0.0002 and p = 0.07), respectively. The mean fluconazole half-lives were 88.6 hours (n = 7), 67.5 hours (n = 9), and 55.2 hours (n = 4; p = 0.3). The mean total clearance corrected for weight (CL/kg) was 0.18 ml/min/kg (n = 7), 0.33 ml/min/kg (n = 7), and 0.52 ml/min/kg (n = 4; p = 0.02), and the mean volume of distribution 1.18 L/kg (n = 7), 1.84 L/kg (n = 7), and 2.25 L/kg (n = 4; p = 0.05). Weight-corrected clearance increased with postnatal age (r = 0.61; p = 0.007). CONCLUSIONS: With the used fluconazole dose (6 mg/kg every 3 days), the mean serum peak and trough concentrations increased during the first week but decreased during the second week. After the first week we suggest a dose of 6 mg/kg every 2 days, or even daily.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The pharmacokinetics of fluconazole vary with age [89][90][91][92].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [91]
In the citing paper
“the pharmacological properties of fluconazole vary with neonatal age, making the choice of dosage somewhat difficult [86,90,91].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [91]
Citations
Cited by
Sorted by citations
Items 101–128 of 128
Pediatric Clinical Endpoint and Pharmacodynamic Biomarkers: Limitations and Opportunities
Dinh, J., Hosey, C. M., & Jones, B. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-019-00375-1 · Cited by 4
Fungal infections in pediatric patients
Groll, A. H., Roilides, E., & Walsh, T. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00022-0 · Cited by 4
Fungal Prophylaxis in the Neonatal Intensive Care Unit
Healy, C. M. (2008) · NeoReviews · doi:10.1542/neo.9-12-e562 · Cited by 3
Pharmacokinetic considerations in treating invasive pediatric fungal infections
Goldman, J. L., & Abdel‐Rahman, S. M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1181752 · Cited by 3
“[80,81] Posaconazole and itraconazole appear to be substrate for the efflux transporter P-glycoprotein (P-gp) which could affect not only clearance, but also intestinal bioavailability and tissue distribution.”
BackgroundBendel, C. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6400-8.00033-x · Cited by 3
Clinical Pharmacology of Fluconazole in Neonates: Effects and Pharmacokinetics
Pacifici, G. M. (2016) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2
Estudio prospectivo de sepsis por Candida en el recién nacido
Caballero, S. J., Caballero, M. P. J., Gutiérrez, F., Zafra, M., Muñoz, M. D. H., Marcos, R. A., Cabañas, J. G., & Martínez, M. Z. (1998) · Anales de Pediatría · Cited by 2
STANDARDS OF MEDICAL CARE “INVASIVE CANDIDIASIS IN NEWBORNS”
Dobryanskyy, D. O., Gulenko, O., Знаменська, Т. К., & Vorobiova, O. V. (2021) · Neonatology surgery and perinatal medicine · doi:10.24061/2413-4260.xi.4.42.2021.12 · Cited by 1
Groll, A. H., & Walsh, T. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50257-0 · Cited by 1
Invasive fungal infections in children: advances and perspectives
Groll, A. H., Köhler, J. R., & Walsh, T. J. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8099-1_16 · Cited by 1
de Batista, G. C. M. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2009.tde-10022010-093505 · Cited by 1
Thrombopénie induite par l'amphotéricine B chez un très grand prématuré avec candidose congénitale
Baud, O., Boithias, C., Lacaze‐Masmonteil, T., et al. (1996) · Archives de Pédiatrie · doi:10.1016/0929-693x(96)82174-9 · Cited by 1
Arthington, B. A., & Frade, J. P. (2010) · Issues in infectious diseases · doi:10.1159/000298761
Infants: Yeasts are beasts in early life
Greenberg, R. G., & Benjamin, D. K. (2019) · CRC Press eBooks · doi:10.1201/9780429402012-27
YEAST AND FUNGAL INFECTIONS OF THE FETUS AND NEONATE
Demmler‐Harrison, G. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50081-9
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00516-7
Smith, P. B., & Benjamin, D. K. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-27
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53272-5.50007-8
ANTIFUNGAL AGENTS IN NEONATAL SYSTEMIC CANDIDIASIS.
&NA; (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199602000-00034
Puia‐Dumitrescu, M., & Benjamin, D. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54391-0.00006-0
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00752-6
Supplementary material A: Commentaries
Ainsworth, S. B. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198840787.005.0001
Wang, H., Li, D., Jiang, Y., Liang, J., Yu, Q., Kuang, L., Huang, Y., Qin, D., Li, P., He, J., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03184-7
“At the same time, owing to the difficulty to obtain samples from infants, most PK studies of infants have small sample size, and the parameters vary among studies (Saxen et al. 1993; Wenzl et al. 1998; Brammer and Coates 1994).”
(2000) · Time to knit · doi:10.1016/s1637-5017(19)30253-4
Groll, A. H., & Walsh, T. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00256-9
Saleem, T., Ameen, K., Rasool, M. F., & Alqahtani, F. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2744221
Metadata
- Authors
- Saxén, H., Hoppu, K., & Pohjavuori, M.
- Affiliations
- University of Helsinki (FI)
- Corresponding author
- Hoppu, Kalle
- ORCID
- Hoppu, Kalle
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1993
- Volume
- 54
- Issue
- 3
- Pages
- 269-277
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1969659982
- Cited by
- 127
- References
- 0
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 4
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- fluconazole, pharmacokinetics, very low birth weight infants, preterm infants, Candida parapsilosis, antifungal prophylaxis, intravenous administration, drug clearance, volume of distribution, half-life, postnatal age
- MeSH terms
- Candidiasis, Female, Half-Life, Humans, Infant, Low Birth Weight, Infant, Newborn, Infant, Premature, Infant, Premature, Diseases, Male, Pilot Projects, Fluconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review